The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been fil ...

Equities researchers at William Blair increased their Q1 2025 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a report released on Monday, March 3rd. William Blair analyst M.

Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...

While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Neumora Therapeutics (NASDAQ:NMRA) stock drops 11% as Stifel downgrades nothing that J&J (JNJ) discontinues a drug similar to NMRA's lead asset. Read more here.

Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") of a class action securities ...

Johnson & Johnson (JNJ) stock in focus as company halts Phase 3 depression therapy trials for aticaprant over efficacy ...